These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 29519558)

  • 1. Preoperative prediction of a pathologic complete response of esophageal squamous cell carcinoma to neoadjuvant chemoradiotherapy.
    Hamai Y; Hihara J; Emi M; Furukawa T; Murakami Y; Nishibuchi I; Nagata Y; Ibuki Y; Yamakita I; Kurokawa T; Okada M
    Surgery; 2018 Mar; ():. PubMed ID: 29519558
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Significance of
    Hamai Y; Hihara J; Emi M; Ibuki Y; Murakami Y; Nishibuchi I; Nagata Y; Aoki Y; Furukawa T; Okada M
    Ann Surg Oncol; 2019 Jun; 26(6):1869-1878. PubMed ID: 30675704
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of quantitative parameters for esophageal squamous cell carcinoma determined by preoperative FDG-PET after trimodal therapy.
    Hamai Y; Emi M; Ibuki Y; Murakami Y; Nishibuchi I; Nagata Y; Kurokawa T; Yoshikawa T; Hirohata R; Ohsawa M; Kitasaki N; Okada M
    Surgery; 2022 Aug; 172(2):584-592. PubMed ID: 35523595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ability of Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography to Predict Outcomes of Neoadjuvant Chemoradiotherapy Followed by Surgical Treatment for Esophageal Squamous Cell Carcinoma.
    Hamai Y; Hihara J; Emi M; Furukawa T; Yamakita I; Kurokawa T; Okada M
    Ann Thorac Surg; 2016 Oct; 102(4):1132-9. PubMed ID: 27319990
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preoperative image-guided identification of response to neoadjuvant chemoradiotherapy in esophageal cancer (PRIDE): a multicenter observational study.
    Borggreve AS; Mook S; Verheij M; Mul VEM; Bergman JJ; Bartels-Rutten A; Ter Beek LC; Beets-Tan RGH; Bennink RJ; van Berge Henegouwen MI; Brosens LAA; Defize IL; van Dieren JM; Dijkstra H; van Hillegersberg R; Hulshof MC; van Laarhoven HWM; Lam MGEH; van Lier ALHMW; Muijs CT; Nagengast WB; Nederveen AJ; Noordzij W; Plukker JTM; van Rossum PSN; Ruurda JP; van Sandick JW; Weusten BLAM; Voncken FEM; Yakar D; Meijer GJ;
    BMC Cancer; 2018 Oct; 18(1):1006. PubMed ID: 30342494
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant chemoradiotherapy with concurrent cisplatin/5-fluorouracil is associated with increased pathologic complete response and improved survival compared to carboplatin/paclitaxel in patients with locally advanced esophageal cancer.
    Haisley KR; Hart KD; Nabavizadeh N; Bensch KG; Vaccaro GM; Thomas CR; Schipper PH; Hunter JG; Dolan JP
    Dis Esophagus; 2017 Jul; 30(7):1-7. PubMed ID: 28475724
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of Repeat 18F-Fluorodeoxyglucose Positron Emission Tomography Examination in Predicting Pathologic Response Following Neoadjuvant Chemoradiotherapy for Esophageal Adenocarcinoma.
    Kukar M; Alnaji RM; Jabi F; Platz TA; Attwood K; Nava H; Ben-David K; Mattson D; Salerno K; Malhotra U; Kanehira K; Gannon J; Hochwald SN
    JAMA Surg; 2015 Jun; 150(6):555-62. PubMed ID: 25902198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Accuracy of detecting residual disease after neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma (preSINO trial): a prospective multicenter diagnostic cohort study.
    Zhang X; Eyck BM; Yang Y; Liu J; Chao YK; Hou MM; Hung TM; Pang Q; Yu ZT; Jiang H; Law S; Wong I; Lam KO; van der Wilk BJ; van der Gaast A; Spaander MCW; Valkema R; Lagarde SM; Wijnhoven BPL; van Lanschot JJB; Li Z
    BMC Cancer; 2020 Mar; 20(1):194. PubMed ID: 32143580
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PET/CT in the evaluation of treatment response to neoadjuvant chemoradiotherapy and prognostication in patients with locally advanced esophageal squamous cell carcinoma.
    Yuan H; Tong DK; Vardhanabhuti V; Law SY; Chiu KW; Khong PL
    Nucl Med Commun; 2016 Sep; 37(9):947-55. PubMed ID: 27145438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoadjuvant Therapy for Locally Advanced Esophageal Cancer Should Be Targeted to Tumor Histology.
    Stiles BM; Kamel MK; Harrison SW; Rahouma M; Lee B; Nasar A; Port JL; Altorki NK
    Ann Thorac Surg; 2019 Jan; 107(1):187-193. PubMed ID: 30278165
    [TBL] [Abstract][Full Text] [Related]  

  • 11. To evaluate the treatment response of locally advanced esophageal cancer after preoperative chemoradiotherapy by FDG-PET/CT scan.
    Huang JW; Yeh HL; Hsu CP; Lu YY; Chuang CY; Lin JC; Lin JF; Chang CF
    J Chin Med Assoc; 2015 Apr; 78(4):229-34. PubMed ID: 25557468
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lack of fludeoxyglucose F 18 uptake in posttreatment positron emission tomography as a significant predictor of survival after subsequent surgery in multimodality treatment for patients with locally advanced esophageal squamous cell carcinoma.
    Higuchi I; Yasuda T; Yano M; Doki Y; Miyata H; Tatsumi M; Fukunaga H; Takiguchi S; Fujiwara Y; Hatazawa J; Monden M
    J Thorac Cardiovasc Surg; 2008 Jul; 136(1):205-12, 212.e1-3. PubMed ID: 18603077
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical tools do not predict pathological complete response in patients with esophageal squamous cell cancer treated with definitive chemoradiotherapy.
    Molena D; Sun HH; Badr AS; Mungo B; Sarkaria IS; Adusumilli PS; Bains MS; Rusch VW; Ilson DH; Rizk NP
    Dis Esophagus; 2014; 27(4):355-9. PubMed ID: 24033404
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diffusion-weighted MRI and
    Xu X; Sun ZY; Wu HW; Zhang CP; Hu B; Rong L; Chen HY; Xie HY; Wang YM; Lin HP; Bai YR; Ye Q; Ma XM
    Radiat Oncol; 2021 Jul; 16(1):132. PubMed ID: 34281566
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive Value of Endoscopic Observations and Biopsy After Neoadjuvant Chemoradiotherapy in Assessing the Pathologic Complete Response of Patients With Esophageal Squamous Cell Carcinoma.
    Taghizadeh Kermani A; Ghanbarzadeh R; Joudi Mashhad M; Javadinia SA; Emadi Torghabeh A
    Front Oncol; 2022; 12():859079. PubMed ID: 35646696
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combining the radiomic features and traditional parameters of
    Chen YH; Lue KH; Chu SC; Chang BS; Wang LY; Liu DW; Liu SH; Chao YK; Chan SC
    Ann Nucl Med; 2019 Sep; 33(9):657-670. PubMed ID: 31218571
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FDG-PET in the prediction of pathologic response after neoadjuvant chemoradiotherapy in locally advanced, resectable esophageal cancer.
    Song SY; Kim JH; Ryu JS; Lee GH; Kim SB; Park SI; Song HY; Cho KJ; Ahn SD; Lee SW; Shin SS; Choi EK
    Int J Radiat Oncol Biol Phys; 2005 Nov; 63(4):1053-9. PubMed ID: 15964705
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preoperative pembrolizumab combined with chemoradiotherapy for esophageal squamous cell carcinoma: Trial design.
    Zheng Y; Li C; Yu B; Zhao S; Li J; Chen X; Li H
    JTCVS Open; 2022 Mar; 9():293-299. PubMed ID: 36003437
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Complete pathologic response after neoadjuvant chemoradiotherapy for esophageal cancer is associated with enhanced survival.
    Donahue JM; Nichols FC; Li Z; Schomas DA; Allen MS; Cassivi SD; Jatoi A; Miller RC; Wigle DA; Shen KR; Deschamps C
    Ann Thorac Surg; 2009 Feb; 87(2):392-8; discussion 398-9. PubMed ID: 19161745
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of postoperative lymph node status on the prognosis of esophageal squamous cell carcinoma after esophagectomy following neoadjuvant chemoradiotherapy: a retrospective study.
    Sun Z; Xu X; Zhao X; Ma X; Ye Q
    J Gastrointest Oncol; 2021 Dec; 12(6):2685-2695. PubMed ID: 35070398
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.